wegovy versus tirzepatide GLP-1 receptor agonists, including semaglutide (Wegovy/Ozempic) and (Mounjaro/Zepbound), are being recognized for benefits beyond blood sugar control and weight management. New real-world evidence suggests they may also play a role in Semaglutide vs Tirzepatide: Which Works

Keep a brief log of energy, appetite, mood, and any physical symptoms for the first 46 weeks

Tirzepatide (Mounjaro, Zepbound) is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

Treat it as expert-opinion scaffolding rather than trial-confirmed criteria

First click = injection started

Tirzepatide works by mimicking two hormonesGLP-1 and GIPthat are naturally involved in appetite regulation

Sodiumglucose cotransporter 2 (SGLT2) inhibitors, also known as Flozins, are a class of medication primarily used to manage type 2 diabetes